{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:39:03Z","timestamp":1787989143385,"version":"build-2784847793"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To critically evaluate evidence supporting the angiogenesis-inflammation hypothesis in diabetic retinopathy (DR); to examine the roles of angiogenic growth factors and inflammatory cytokines in the biphasic effects of insulin on DR - early worsening followed by long-term risk reduction; and to explore broader implications of this hypothesis, including potential biphasic effects of semaglutide due to its insulinotropic action and strategies to mitigate the transient DR exacerbation associated with insulin and insulin secretagogues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Literature review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Hyperglycemia and the accumulation of advanced glycation end products upregulate angiogenic growth factors and inflammatory cytokines, notably vascular endothelial growth factor (VEGF) and angiopoietin-2. These mediators compromise the retinal neurovascular unit and disrupt the blood-retinal barrier, while promoting endothelial adhesion molecule expression. The resulting leukostasis triggers hypoxia, leukocyte activation, and self-perpetuating ischemic-inflammatory loops. Insulin-like growth factor-1 further enhances retinal VEGF and angiopoietin-2 expression, potentially driving DR to the proliferative stage. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has paradoxically been linked to DR deterioration like insulin therapy. In contrast, insulin-independent antidiabetic agents such as empagliflozin and metformin are not associated with DR worsening and may even slow its progression. GLP-1 augments glucose-induced insulin secretion, whereas insulin itself upregulates retinal VEGF and angiopoietin-2 and exerts pro-inflammatory effects in insulin-resistant states. Despite early worsening, long-term insulin therapy reduces DR risk through sustained glycemic control, with benefits outweighing initial harm. Semaglutide addresses a broader spectrum of systemic risk factors for DR than insulin, including hypertension, dyslipidemia, chronic kidney disease, and obesity. In addition, experimental evidence suggests that semaglutide may provide direct neurovascular protection through activation of the retinal GLP-1 receptor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The early worsening of DR associated with insulin therapy may be more accurately attributed to insulin\u2019s pro-angiogenic effects rather than solely to rapid glycemic correction. As an insulin secretagogue, semaglutide may similarly cause early DR progression. However, long-term semaglutide therapy is anticipated to reduce DR risk by improving glycemic control, addressing a broader range of systemic risk factors compared with insulin, and offering direct neurovascular protection in the retina. Combination therapy with insulin-independent glucose-lowering agents may help mitigate the transient DR deterioration linked to insulin and insulin secretagogues.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00811-8","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:48:18Z","timestamp":1773823698000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide \u2013 a review"],"prefix":"10.1186","volume":"12","author":[{"given":"Ming","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"11","key":"811_CR1","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47(11):1873\u201388.","journal-title":"Diabetes Care"},{"issue":"19","key":"811_CR2","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"811_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/dom.13172","volume":"20","author":"T Vilsb\u00f8ll","year":"2018","unstructured":"Vilsb\u00f8ll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889\u201397.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"811_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2337\/dc13-2251","volume":"37","author":"LP Aiello","year":"2014","unstructured":"Aiello LP, DCCT\/EDIC Research Group. Diabetic retinopathy and other ocular findings in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):17\u201323.","journal-title":"Diabetes Care"},{"issue":"2","key":"811_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/(SICI)1096-9136(199702)14:2<123::AID-DIA306>3.0.CO;2-U","volume":"14","author":"M Henricsson","year":"1997","unstructured":"Henricsson M, Nilsson A, Janzon L, Groop L. The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med. 1997;14(2):123\u201331.","journal-title":"Diabet Med"},{"issue":"1","key":"811_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/jamaophthalmol.2024.5219","volume":"143","author":"H Tesfaye","year":"2025","unstructured":"Tesfaye H, Paik JM, Roh M, et al. Empagliflozin and the risk of retinopathy in patients with type 2 diabetes. JAMA Ophthalmol. 2025;143(1):62\u201371.","journal-title":"JAMA Ophthalmol"},{"key":"811_CR7","doi-asserted-by":"publisher","first-page":"9161039","DOI":"10.1155\/2020\/9161039","volume":"2020","author":"YP Fan","year":"2020","unstructured":"Fan YP, Wu CT, Lin JL, et al. Metformin treatment is associated with a decreased risk of nonproliferative diabetic retinopathy in patients with type 2 diabetes mellitus: A Population-Based cohort study. J Diabetes Res. 2020;2020:9161039.","journal-title":"J Diabetes Res"},{"key":"811_CR8","doi-asserted-by":"publisher","first-page":"2801450","DOI":"10.1155\/2018\/2801450","volume":"2018","author":"Y Li","year":"2018","unstructured":"Li Y, Ryu C, Munie M, et al. Association of Metformin treatment with reduced severity of diabetic retinopathy in type 2 diabetic patients. J Diabetes Res. 2018;2018:2801450.","journal-title":"J Diabetes Res"},{"issue":"3","key":"811_CR9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/dom.13538","volume":"21","author":"SC Bain","year":"2019","unstructured":"Bain SC, Klufas MA, Ho A, et al. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. Diabetes Obes Metab. 2019;21(3):454\u201366.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"811_CR10","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1111\/aos.15724","volume":"102","author":"A Hatamnejad","year":"2024","unstructured":"Hatamnejad A, Orr S, Dadak R, et al. Anti-VEGF and steroid combination therapy relative to anti-VEGF mono therapy for the treatment of refractory DME: A systematic review of efficacy and meta-analysis of safety. Acta Ophthalmol. 2024;102(3):e204\u201314.","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"811_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2337\/db19-1121","volume":"69","author":"M Arima","year":"2020","unstructured":"Arima M, Nakao S, Yamaguchi M, et al. Claudin-5 redistribution induced by inflammation leads to Anti-VEGF-Resistant diabetic macular edema. Diabetes. 2020;69(5):981\u201399.","journal-title":"Diabetes"},{"key":"811_CR12","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes*; 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes\u20142026. Diabetes Care 2026;49(Supplement_1):S261\u2013S276.","DOI":"10.2337\/dc26-S012"},{"issue":"15","key":"811_CR13","doi-asserted-by":"publisher","first-page":"8513","DOI":"10.3390\/ijms23158513","volume":"23","author":"R Sim\u00f3","year":"2022","unstructured":"Sim\u00f3 R, Hern\u00e1ndez C. New insights into treating early and advanced stage diabetic retinopathy. Int J Mol Sci. 2022;23(15):8513.","journal-title":"Int J Mol Sci"},{"key":"811_CR14","unstructured":"Lu M. Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. MD Thesis, Harvard Medical School. 1999, Boston, MA."},{"issue":"1","key":"811_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0896-1549(01)00010-4","volume":"15","author":"M Lu","year":"2002","unstructured":"Lu M, Adamis AP. Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. Ophthalmol Clin North Am. 2002;15(1):69\u201379.","journal-title":"Ophthalmol Clin North Am"},{"issue":"11","key":"811_CR16","first-page":"1","volume":"1","author":"SF Abcouwer","year":"2013","unstructured":"Abcouwer SF. Angiogenic factors and cytokines in diabetic retinopathy. J Clin Cell Immunol. Suppl 2013;1(11):1\u201312.","journal-title":"J Clin Cell Immunol"},{"issue":"11","key":"811_CR17","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1002\/jcb.25575","volume":"117","author":"M Capit\u00e3o","year":"2016","unstructured":"Capit\u00e3o M, Soares R. Angiogenesis and inflammation crosstalk in diabetic retinopathy. J Cell Biochem. 2016;117(11):2443\u201353.","journal-title":"J Cell Biochem"},{"issue":"7","key":"811_CR18","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.3390\/ijms22073427","volume":"22","author":"H Noma","year":"2021","unstructured":"Noma H, Yasuda K, Shimura M. Involvement of cytokines in the pathogenesis of diabetic macular edema. Int J Mol Sci. 2021;22(7):3427.","journal-title":"Int J Mol Sci"},{"issue":"11\u201312","key":"811_CR19","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s13300-022-01326-9","volume":"13","author":"JD Collazos-Alem\u00e1n","year":"2022","unstructured":"Collazos-Alem\u00e1n JD, Gnecco-Gonz\u00e1lez S, Jaramillo-Zarama B, et al. The role of angiopoietins in neovascular Diabetes-Related retinal diseases. Diabetes Ther. 2022;13(11\u201312):1811\u201321.","journal-title":"Diabetes Ther"},{"issue":"22","key":"811_CR20","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480\u20137.","journal-title":"N Engl J Med"},{"issue":"11","key":"811_CR21","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/S0161-6420(96)30420-X","volume":"103","author":"MJ Tolentino","year":"1996","unstructured":"Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103(11):1820\u20138.","journal-title":"Ophthalmology"},{"issue":"8","key":"811_CR22","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/archopht.1996.01100140172010","volume":"114","author":"MJ Tolentino","year":"1996","unstructured":"Tolentino MJ, Miller JW, Gragoudas ES, et al. Vascular endothelial growth factor is sufficient to produce Iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1996;114(8):964\u201370.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"811_CR23","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: Two-Year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351\u20139.","journal-title":"Ophthalmology"},{"issue":"10432","key":"811_CR24","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, et al. Intravitreal Aflibercept 8\u00a0mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet. 2024;403(10432):1153\u201363.","journal-title":"Lancet"},{"key":"811_CR25","doi-asserted-by":"crossref","unstructured":"Maturi RK, Glassman AR, Josic K, et al. Four-year visual outcomes in the protocol W randomized trial of intravitreous aflibercept for prevention of vision-threatening complications of diabetic retinopathy [published correction appears in JAMA. 2023;329(12):1034.]. JAMA. 2023;329(5):376\u2013385.","DOI":"10.1001\/jama.2023.6715"},{"issue":"6","key":"811_CR26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, et al. Faricimab Treat-and-Extend for diabetic macular edema: Two-Year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024;131(6):708\u201323.","journal-title":"Ophthalmology"},{"issue":"10","key":"811_CR27","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2337\/diacare.46.10.1619","volume":"46","author":"RS Punglia","year":"1997","unstructured":"Punglia RS, Lu M, Hsu J, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes. 1997;46(10):1619\u201326.","journal-title":"Diabetes"},{"issue":"2","key":"811_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0002-9440(10)63311-1","volume":"165","author":"V Poulaki","year":"2004","unstructured":"Poulaki V, Joussen AM, Mitsiades N, et al. Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol. 2004;165(2):457\u201369.","journal-title":"Am J Pathol"},{"issue":"6","key":"811_CR29","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI116877","volume":"92","author":"R Meyer-Schwickerath","year":"1993","unstructured":"Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest. 1993;92(6):2620\u20135.","journal-title":"J Clin Invest"},{"issue":"1","key":"811_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13098-022-00806-z","volume":"14","author":"TE Wu","year":"2022","unstructured":"Wu TE, Chen HS. The role of growth hormone and IGF-1 in retinopathy: a prospective study of retinopathy in patients with acromegaly and impaired fasting glucose. Diabetol Metab Syndr. 2022;14(1):38.","journal-title":"Diabetol Metab Syndr"},{"issue":"11","key":"811_CR31","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/biom13111630","volume":"13","author":"R Al-Dwairi","year":"2023","unstructured":"Al-Dwairi R, El-Elimat T, Aleshawi A, et al. Vitreous levels of vascular endothelial growth factor and Platelet-Derived growth factor in patients with proliferative diabetic retinopathy: A clinical correlation. Biomolecules. 2023;13(11):1630.","journal-title":"Biomolecules"},{"issue":"1","key":"811_CR32","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1186\/s12967-025-07075-0","volume":"23","author":"L Cao","year":"2025","unstructured":"Cao L, Ding L, Xia Q, et al. Macrophage polarization in diabetic vascular complications: mechanistic insights and therapeutic targets. J Transl Med. 2025;23(1):1050.","journal-title":"J Transl Med"},{"key":"811_CR33","doi-asserted-by":"crossref","unstructured":"Mason RH, Minaker SA, Lahaie Luna G, et al. Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis. Eye (Lond). Published online June 7, 2022.","DOI":"10.1038\/s41433-022-02127-x"},{"issue":"19","key":"811_CR34","doi-asserted-by":"publisher","first-page":"10836","DOI":"10.1073\/pnas.96.19.10836","volume":"96","author":"K Miyamoto","year":"1999","unstructured":"Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 Inhibition. Proc Natl Acad Sci U S A. 1999;96(19):10836\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"811_CR35","doi-asserted-by":"publisher","first-page":"e95530","DOI":"10.1172\/jci.insight.95530","volume":"2","author":"Y Liu","year":"2017","unstructured":"Liu Y, Shen J, Fortmann SD, et al. Reversible retinal vessel closure from VEGF-induced leukocyte plugging. JCI Insight. 2017;2(18):e95530.","journal-title":"JCI Insight"},{"key":"811_CR36","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00417-020-04956-6","volume":"259","author":"Y Yao","year":"2021","unstructured":"Yao Y, Cai Y, Sui A, et al. Etanercept as a TNF-alpha inhibitor depresses experimental retinal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2021;259:661\u201371.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"811_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nm1351","volume":"12","author":"U Fiedler","year":"2006","unstructured":"Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-\u03b1 and has a crucial role in the induction of inflammation. Nat Med. 2006;12:235\u20139.","journal-title":"Nat Med"},{"issue":"13","key":"811_CR38","doi-asserted-by":"publisher","first-page":"7142","DOI":"10.3390\/ijms22137142","volume":"22","author":"SSR Iyer","year":"2021","unstructured":"Iyer SSR, Lagrew MK, Tillit SM, et al. The vitreous ecosystem in diabetic retinopathy: insight into the Patho-Mechanisms of disease. Int J Mol Sci. 2021;22(13):7142.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"811_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1465-9921-7-37","volume":"7","author":"Q Tong","year":"2006","unstructured":"Tong Q, Zheng L, Lin L, et al. VEGF is upregulated by hypoxia-induced mitogenic factor via the PI-3K\/Akt-NF-kappaB signaling pathway. Respir Res. 2006;7(1):37.","journal-title":"Respir Res"},{"issue":"3","key":"811_CR40","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cardiores.2004.09.032","volume":"65","author":"G Pag\u00e8s","year":"2005","unstructured":"Pag\u00e8s G, Pouyss\u00e9gur J. Transcriptional regulation of the vascular endothelial growth factor gene\u2013a concert of activating factors. Cardiovasc Res. 2005;65(3):564\u201373.","journal-title":"Cardiovasc Res"},{"key":"811_CR41","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1017\/erm.2023.20","volume":"25","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Zhang J, Shi C, et al. NF-\u03baB: a mediator that promotes or inhibits angiogenesis in human diseases? Expert Rev Mol Med. 2023;25:e25.","journal-title":"Expert Rev Mol Med"},{"issue":"2","key":"811_CR42","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0167-4781(97)00052-3","volume":"1352","author":"NS Levy","year":"1997","unstructured":"Levy NS, Goldberg MA, Levy AP. Sequencing of the human vascular endothelial growth factor (VEGF) 3\u2032 untranslated region (UTR): conservation of five hypoxia-inducible RNA-protein binding sites. Biochim Et Biophys Acta (BBA) - Gene Struct Expression. 1997;1352(2):167\u201373.","journal-title":"Biochim Et Biophys Acta (BBA) - Gene Struct Expression"},{"issue":"9","key":"811_CR43","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.2337\/diab.46.9.1497","volume":"46","author":"B Williams","year":"1997","unstructured":"Williams B, Gallacher B, Patel H, Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes. 1997;46(9):1497\u2013503.","journal-title":"Diabetes"},{"issue":"13","key":"811_CR44","doi-asserted-by":"crossref","first-page":"8723","DOI":"10.1074\/jbc.272.13.8723","volume":"272","author":"H Yamagishi Si, Yonekura","year":"1997","unstructured":"Yamagishi Si, Yonekura H, Yamamoto Y, et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem. 1997;272(13):8723\u201330.","journal-title":"J Biol Chem"},{"issue":"6","key":"811_CR45","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1172\/JCI1277","volume":"101","author":"M Lu","year":"1998","unstructured":"Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101(6):1219\u201324.","journal-title":"J Clin Invest"},{"issue":"13","key":"811_CR46","first-page":"3281","volume":"40","author":"M Lu","year":"1999","unstructured":"Lu M, Amano S, Miyamoto K, et al. Insulin-induced vascular endothelial growth factor expression in retina. Invest Ophthalmol Vis Sci. 1999;40(13):3281\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"811_CR47","first-page":"1808","volume":"40","author":"M Lu","year":"1999","unstructured":"Lu M, Perez VL, Ma N, et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci. 1999;40(8):1808\u201312.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl 2","key":"811_CR48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1464-5491.2008.02505.x","volume":"25","author":"EM Kohner","year":"2008","unstructured":"Kohner EM. Microvascular disease: what does the UKPDS tell Us about diabetic retinopathy? Diabet Med. 2008;25(Suppl 2):20\u20134.","journal-title":"Diabet Med"},{"key":"811_CR49","doi-asserted-by":"publisher","first-page":"1303238","DOI":"10.3389\/fendo.2023.1303238","volume":"14","author":"L Tan","year":"2024","unstructured":"Tan L, Wang Z, Okoth K, et al. Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis. Front Endocrinol (Lausanne). 2024;14:1303238.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"811_CR50","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1172\/JCI0213776","volume":"109","author":"V Poulaki","year":"2002","unstructured":"Poulaki V, Qin W, Joussen AM, et al. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest. 2002;109(6):805\u201315.","journal-title":"J Clin Invest"},{"key":"811_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.06.016","volume":"307","author":"S Chandel","year":"2020","unstructured":"Chandel S, Sathis A, Dhar M, et al. Hyperinsulinemia promotes endothelial inflammation via increased expression and release of Angiopoietin-2. Atherosclerosis. 2020;307:1\u201310.","journal-title":"Atherosclerosis"},{"issue":"1","key":"811_CR52","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","volume":"7","author":"M Li","year":"2022","unstructured":"Li M, Chi X, Wang Y, et al. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. 2022;7(1):216.","journal-title":"Signal Transduct Target Ther"},{"key":"811_CR53","doi-asserted-by":"crossref","unstructured":"Zhang A, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in obesity, inflammation, and cancer. Diabetes Metab J. 2021;45(3):285\u2013311. Epub 2021 Mar 29. Erratum in: Diabetes Metab J. 2021;45(4):622.","DOI":"10.4093\/dmj.2020.0250"},{"key":"811_CR54","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). [published correction appears in Lancet 1999;354(9178):602]. Lancet. 1998;352(9131):837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"811_CR55","unstructured":"Lu M. Signal transduction of the endogenous and recombinant glucagon-like peptide-1 receptor. 1993. PhD Dissertation, Baylor College of Medicine. Houston, TX."},{"issue":"1","key":"811_CR56","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1210\/endo.132.1.8380389","volume":"132","author":"M Lu","year":"1993","unstructured":"Lu M, Wheeler MB, Leng XH, et al. The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7\u201337). Endocrinology. 1993;132(1):94\u2013100.","journal-title":"Endocrinology"},{"key":"811_CR57","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2337\/dbi19-0005","volume":"68","author":"MA Nauck","year":"2019","unstructured":"Nauck MA, Meier JJ. GIP and GLP-1: stepsiblings rather than monozygotic twins within the incretin family. Diabetes. 2019;68:897.","journal-title":"Diabetes"},{"issue":"4","key":"811_CR58","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.diabet.2018.03.004","volume":"44","author":"NH Kim","year":"2018","unstructured":"Kim NH, Choi J, Kim NH, et al. Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study. Diabetes Metab. 2018;44(4):361\u20137.","journal-title":"Diabetes Metab"},{"issue":"12","key":"811_CR59","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1097\/IAE.0000000000001098","volume":"36","author":"YR Chung","year":"2016","unstructured":"Chung YR, Park SW, Kim JW, et al. PROTECTIVE EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON PROGRESSION OF DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES. Retina. 2016;36(12):2357\u201363.","journal-title":"Retina"},{"issue":"10","key":"811_CR60","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","volume":"84","author":"DJ Drucker","year":"1987","unstructured":"Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide I stimulates insulin gene expression and increases Cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA. 1987;84(10):3434\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"811_CR61","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72\u2013130.","journal-title":"Mol Metab"},{"issue":"10","key":"811_CR62","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1210\/mend.15.10.0702","volume":"15","author":"MC Lawrence","year":"2001","unstructured":"Lawrence MC, Bhatt HS, Watterson JM, Easom RA. Regulation of insulin gene transcription by a Ca(2+)-responsive pathway involving calcineurin and nuclear factor of activated T cells. Mol Endocrinol. 2001;15(10):1758\u201367.","journal-title":"Mol Endocrinol"},{"key":"811_CR63","first-page":"42","volume":"106","author":"M Lu","year":"1993","unstructured":"Lu M, Wheeler MB, Leng XH, et al. Stimulation of insulin secretion and insulin gene expression by gastric inhibitory polypeptide. Trans Assoc Am Physicians. 1993;106:42\u201353.","journal-title":"Trans Assoc Am Physicians"},{"key":"811_CR64","doi-asserted-by":"crossref","unstructured":"Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811\u201324.","DOI":"10.1016\/S0140-6736(21)02188-7"},{"key":"811_CR65","doi-asserted-by":"crossref","unstructured":"Fr\u00edas JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563\u201374.","DOI":"10.1016\/S2213-8587(21)00174-1"},{"key":"811_CR66","doi-asserted-by":"crossref","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234.","DOI":"10.1038\/s41392-024-01931-z"},{"key":"811_CR67","doi-asserted-by":"crossref","unstructured":"Xie Z, Yang Z, Tian D, Chen Y. Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact. Front Pharmacol. 2025;16:1618079.","DOI":"10.3389\/fphar.2025.1618079"},{"key":"811_CR68","doi-asserted-by":"crossref","unstructured":"Bendotti G, Montefusco L, Lunati ME, et al. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacol Res. 2022;182:106320.","DOI":"10.1016\/j.phrs.2022.106320"},{"key":"811_CR69","doi-asserted-by":"crossref","unstructured":"Ren Y, Chen Y, Zheng W, et al. The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta-analysis. Diabetes Obes Metab. 2025;27(7):3607\u201326.","DOI":"10.1111\/dom.16366"},{"key":"811_CR70","doi-asserted-by":"crossref","unstructured":"Cheng X, Fu Z, Chen Y, Wang Y, Han F. Semaglutide attenuates diabetic retinopathy progression via ameliorating retinal vasculopathy and oxidative stress in vivo and in vitro. Diabetes Obes Metab. 2025;1\u201312.","DOI":"10.1111\/dom.70107"},{"key":"811_CR71","doi-asserted-by":"crossref","unstructured":"Anastasiou IA, Tentolouris A, Sarantis P, Katsaouni A, Rebelos E, Mourouzis I, et al. Semaglutide Enhances Cellular Regeneration in Skin and Retinal Cells In Vitro. Pharmaceutics. 2025;17(9):1115.","DOI":"10.3390\/pharmaceutics17091115"},{"key":"811_CR72","doi-asserted-by":"crossref","unstructured":"Suzuma I, Hata Y, Clermont A, Pokras F, Rook SL, Suzuma K, et al. Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension. Diabetes. 2001;50(2):444\u201354.","DOI":"10.2337\/diabetes.50.2.444"},{"key":"811_CR73","doi-asserted-by":"crossref","unstructured":"Zhang X, Lassila M, Cooper ME, Cao Z. Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension. 2004;43(2):276\u201381.","DOI":"10.1161\/01.HYP.0000113628.94574.0f"},{"key":"811_CR74","doi-asserted-by":"crossref","unstructured":"Fu D, Yu JY, Wu M, Du M, Chen Y, Abdelsamie SA, et al. Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytes. J Lipid Res. 2014;55(5):860\u201369.","DOI":"10.1194\/jlr.M045401"},{"key":"811_CR75","unstructured":"Lai S, Perrotta AM, Bagordo D, Mazzaferro S, Men\u00e8 P, Errigo F, et al. Literature review on the cross-link between ocular and renal disease: renin angiotensin aldosterone system is a main actor. Eur Rev Med Pharmacol Sci. 2022;26(13):4774\u201388."},{"key":"811_CR76","doi-asserted-by":"crossref","unstructured":"Esser N, Utzschneider KM, Kahn SE. Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia. Diabetologia. 2020;63(10):2007\u201321.","DOI":"10.1007\/s00125-020-05245-x"},{"key":"811_CR77","doi-asserted-by":"crossref","unstructured":"Simonson M, Li Y, Zhu B, McAnany JJ, Chirakalwasan N, Sutabutr Vajaranant T, et al. Multidimensional sleep health and diabetic retinopathy: Systematic review and metaanalysis. Sleep Med Rev. 2024;74:101891.","DOI":"10.1016\/j.smrv.2023.101891"},{"key":"811_CR78","doi-asserted-by":"crossref","unstructured":"Perez AM, Neag E, Sridhar J, Williams BK Jr. Weight loss, bariatric surgery, and novel antidiabetic drugs effects on diabetic retinopathy: a review. Curr Opin Ophthalmol. 2024;35(3):192\u20136.","DOI":"10.1097\/ICU.0000000000001038"},{"key":"811_CR79","doi-asserted-by":"crossref","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391.","DOI":"10.1038\/s41591-022-02026-4"},{"key":"811_CR80","doi-asserted-by":"crossref","unstructured":"Kennedy C, Hayes P, Cicero AFG, Dobner S, Le Roux CW, McEvoy JW, et al. Semaglutide and blood pressure: an individual patient data metaanalysis. Eur Heart J. 2024;45(38):4124\u201334.","DOI":"10.1093\/eurheartj\/ehae564"},{"key":"811_CR81","unstructured":"Novo Nordisk A\/S. A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS) (NCT03811561). 2025, August 12. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/study\/NCT03811561"},{"key":"811_CR82","doi-asserted-by":"crossref","unstructured":"Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025;27(1):1\u20139.","DOI":"10.1089\/dia.2024.0328"},{"key":"811_CR83","doi-asserted-by":"crossref","unstructured":"Al Ozairi E, Irshad M, Alkandari J, Sojan L, Alroudhan D, Alotaibi N, et al. Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide. Diabetes Obes Metab. 2026;28(1):166\u201373.","DOI":"10.1111\/dom.70172"},{"key":"811_CR84","doi-asserted-by":"crossref","unstructured":"Joo JH, Sharma N, Shaia J, Wu AK, Skugor M, Singh RP, et al. The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Diabetic Retinopathy at a Tertiary Care Center. Ophthalmol Sci. 2024;4(6):100547.","DOI":"10.1016\/j.xops.2024.100547"},{"key":"811_CR85","doi-asserted-by":"crossref","unstructured":"Zheng D, Li N, Hou R, Zhang X, Wu L, Sundquist J, et al. Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies. BMC Med. 2023;21(1):40.","DOI":"10.1186\/s12916-023-02753-6"},{"key":"811_CR86","doi-asserted-by":"crossref","unstructured":"Ramsey DJ, Makwana B, Dani SS, Patel M, Panchal K, Shah J, et al. GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes. JAMA Netw Open. 2025;8(8):e2526321.","DOI":"10.1001\/jamanetworkopen.2025.26321"},{"key":"811_CR87","doi-asserted-by":"crossref","unstructured":"Bahardoust M, Mehrabi Y, Hadaegh F, Khalili D, Delpisheh A. Impact of duration of treatments with metformin and sulfonylureas, individually or in combination, on diabetic retinopathy among newly diagnosed type 2 diabetic patients: a pooled cohort's analysis. Int J Retina Vitreous. 2025;11(1):9.","DOI":"10.1186\/s40942-025-00658-5"},{"key":"811_CR88","doi-asserted-by":"crossref","unstructured":"Taylor SI, Yazdi ZS, Beitelshees AL. Pharmacological treatment of hyperglycemia in type 2 diabetes. J Clin Invest. 2021;131(2):e142243.","DOI":"10.1172\/JCI142243"},{"key":"811_CR89","doi-asserted-by":"crossref","unstructured":"Li JX, Hung YT, Bair H, Hsu SB, Hsu CY, Lin CJ. Sodium-glucose co-transporter 2 inhibitor add-on therapy for metformin delays diabetic retinopathy progression in diabetes patients: a population-based cohort study. Sci Rep. 2023;13(1):17049.","DOI":"10.1038\/s41598-023-43893-2"},{"issue":"3","key":"811_CR90","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.3390\/ijms24032927","volume":"24","author":"T Oshitari","year":"2023","unstructured":"Oshitari T. Advanced glycation End-Products and diabetic neuropathy of the retina. Int J Mol Sci. 2023;24(3):2927.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"811_CR91","doi-asserted-by":"publisher","first-page":"10972","DOI":"10.1073\/pnas.200377097","volume":"97","author":"MD Mueller","year":"2000","unstructured":"Mueller MD, Vigne JL, Minchenko A, et al. Regulation of vascular endothelial growth factor (VEGF) gene transcription by Estrogen receptors alpha and beta. Proc Natl Acad Sci USA. 2000;97(20):10972\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"811_CR92","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0024-3205(96)00253-6","volume":"59","author":"H Sone","year":"1996","unstructured":"Sone H, Okuda Y, Kawakami Y, et al. Progesterone induces vascular endothelial growth factor on retinal pigment epithelial cells in culture. Life Sci. 1996;59(1):21\u20135.","journal-title":"Life Sci"},{"issue":"10","key":"811_CR93","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1111\/ajt.15924","volume":"20","author":"B Voglov\u00e1","year":"2020","unstructured":"Voglov\u00e1 B, Hlad\u00edkov\u00e1 Z, Nem\u00e9tov\u00e1 L, et al. Early worsening of diabetic retinopathy after simultaneous pancreas and kidney transplantation-Myth or reality? Am J Transpl. 2020;20(10):2832\u201341.","journal-title":"Am J Transpl"},{"issue":"1","key":"811_CR94","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/11206721241247585","volume":"35","author":"J Chen","year":"2025","unstructured":"Chen J, Zhang S, You Y, et al. Investigating the impact of empagliflozin on the retina of diabetic mice. Eur J Ophthalmol. 2025;35(1):252\u201361.","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"811_CR95","doi-asserted-by":"publisher","first-page":"BSR20212209","DOI":"10.1042\/BSR20212209","volume":"42","author":"J Matthews","year":"2022","unstructured":"Matthews J, Herat L, Rooney J, et al. Determining the role of SGLT2 Inhibition with empagliflozin in the development of diabetic retinopathy. Biosci Rep. 2022;42(3):BSR20212209.","journal-title":"Biosci Rep"},{"key":"811_CR96","doi-asserted-by":"publisher","first-page":"118065","DOI":"10.1016\/j.ejmech.2025.118065","volume":"299","author":"A Ullah","year":"2025","unstructured":"Ullah A, Shen B. Immunomodulatory effects of anti-diabetic therapies: cytokine and chemokine modulation by metformin, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists (2013\u20132025). Eur J Med Chem. 2025;299:118065.","journal-title":"Eur J Med Chem"},{"issue":"7","key":"811_CR97","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00125-024-06132-5","volume":"67","author":"A Eleftheriadou","year":"2024","unstructured":"Eleftheriadou A, Riley D, Zhao SS, et al. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database. Diabetologia. 2024;67(7):1271\u201382.","journal-title":"Diabetologia"},{"key":"811_CR98","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000098504","volume":"39","author":"C Starita","year":"2007","unstructured":"Starita C, Patel M, Katz B, Adamis AP. Vascular endothelial growth factor and the potential therapeutic use of Pegaptanib (macugen) in diabetic retinopathy. Dev Ophthalmol. 2007;39:122\u201348.","journal-title":"Dev Ophthalmol"},{"issue":"1","key":"811_CR99","doi-asserted-by":"publisher","first-page":"100228","DOI":"10.1016\/j.xops.2022.100228","volume":"3","author":"JI Lim","year":"2022","unstructured":"Lim JI, Regillo CD, Sadda SR, et al. Artificial intelligence detection of diabetic retinopathy: subgroup comparison of the eyeart system with ophthalmologists\u2019 dilated examinations. Ophthalmol Sci. 2022;3(1):100228.","journal-title":"Ophthalmol Sci"},{"key":"811_CR100","doi-asserted-by":"crossref","unstructured":"Lee MK, Kim B, Han K, et al. Sodium-glucose cotransporter 2 inhibitors and risk of retinal vein occlusion among patients with type 2 diabetes: a propensity score-matched cohort study. Diabetes Care. Published online July 22, 2021.","DOI":"10.2337\/figshare.14824089.v1"},{"key":"811_CR101","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes*. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S183-S215.","DOI":"10.2337\/dc26-S009"},{"issue":"9","key":"811_CR102","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s00125-025-06466-8","volume":"68","author":"AJ Buckley","year":"2025","unstructured":"Buckley AJ, Tan GD, Gruszka-Goh M, et al. Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study. Diabetologia. 2025;68(9):2069\u201376.","journal-title":"Diabetologia"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00811-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00811-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00811-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:02:54Z","timestamp":1782730974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00811-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00811-8","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The online version of this article has been updated to correct errors in the reference citations.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}